Overall survival predictors in hepatocellular carcinoma patients treated with sorafenib.

Caroline Petersen da Costa Ferreira Mauricio Alves Ribeiro Luiz Arnaldo Szutan

Published in: Revista da Associacao Medica Brasileira (1992) (2020)

Absence of portal thrombosis, Child-Pugh A, longer time of medication use, ECOG PS 0, and absence of suspension due to clinical worsening were predictors of better overall survival in the study. The drug's indication complies with BCLC guidelines in 94% of patients.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
pulmonary embolism
prognostic factors
free survival
adverse drug
electronic health record